Development of membrane electrodes for selective determination of lisinopril in pharmaceuticals

Lisinopril (LNP) is an angiotensin-converting enzyme inhibitor used as anti-hypertensive, cardiovascular, in anti-prophylactic and anti-diabetic nephropathy drug. Development of two new, simple, low cost, and selective membrane-based ion-selective electrodes has been proposed for the determination of LNP in pharmaceuticals. The electrodes are based on poly(vinyl)chloride membrane doped with LNP-phosphotungstic acid (LNP-PTA) and LNP-phosphomolybdic acid (LNP-PMA) ion-pairs as molecular recognition materials. The developed LNP-PTA and LNP-PMA electrodes are applicable for the determination of LNP over the linear range of 5 × 10−5–2.4 × 10−3 mol l−1. The working pH ranges to measure potentials were 2.5 to 6.4 and 2.3 to 6.0 for LNP-PTA and LNP-PMA ISEs, respectively. The electrodes displayed the rapid Nernstian responses as revealed by the values of slopes 55.06 and 52.39 mV/decade, with limit of detection (LOD) values of 1.2 × 10−5 and 1.18 × 10−5 mol l−1 for LNP-PTA and LNP-PMA electrodes, respectively. The limits of quantitation (LOQ) values have also been calculated for both the electrodes. The developed electrodes have potential stability for up to 1 month and emerged as highly selective for the determination of LNP over other spiked ions and compounds. The proposed electrodes have been validated and found that they are suitable for the determination of LNP in pharmaceuticals in pure form and in dosage forms. The results obtained in the analysis of LNP using proposed electrodes have been compared statistically with reference method’s results to assess the accuracy and precision. Robustness and ruggedness of the developed electrodes have also been checked and found satisfactory. The recovery studies have been performed by standard addition procedure to assess the role of excipients in tablets containing LNP and the results obtained are satisfactory.